# Mocertatug rezetecan PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/mocertatug-rezetecan

> The next catalyst for mocertatug rezetecan, sponsored by GSK plc (GSK), is its topline data readout, Feb to May 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | mocertatug rezetecan |
| Codes |  |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | [Neoplasms, Endometrial](https://sec-api.dev/indications/neoplasms-endometrial), [Ovarian Neoplasms](https://sec-api.dev/indications/ovarian-neoplasms) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Feb to May 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Neoplasms, Endometrial.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07286331 (A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07286331

### February 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Neoplasms, Endometrial.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07286331 (A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07286331

### Jul to Oct 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Neoplasms, Endometrial.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07684599 (A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07684599

### July 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Neoplasms, Endometrial.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07684599 (A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07684599

### Sep to Dec 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Ovarian Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07694427 (Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-06 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07694427

### September 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Ovarian Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07694427 (Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-06 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07694427

### Jul to Oct 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Ovarian Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07286266 (A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-22 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07286266

### July 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Ovarian Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07286266 (A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-22 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07286266

## Same indication

- [Mocertatug rezetecan (mo-rez)](https://sec-api.dev/pdufa/mocertatug-rezetecan-mo-rez) (GSK)
- [ZEJULA (niraparib)](https://sec-api.dev/pdufa/niraparib) (GSK)
- [Sofetabart mipitecan](https://sec-api.dev/pdufa/sofetabart-mipitecan) (LLY)

Calendar months: [February 2028](https://sec-api.dev/fda-calendar/2028-02)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/mocertatug-rezetecan.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Mocertatug rezetecan PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/mocertatug-rezetecan

```bibtex
@misc{secapidev_pdufa_mocertatug_rezetecan_20261116,
  title        = {Mocertatug rezetecan PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/mocertatug-rezetecan}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_mocertatug_rezetecan_20261116","title":"Mocertatug rezetecan PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/mocertatug-rezetecan","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
